Rituximab
Cross-source consensus on Rituximab from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Risks & contraindications
Evidence quality
Highlighted claims
- Only 23.6% of patients underwent immunohistochemistry, and 25 of those patients received rituximab primarily for CD20-positive disease. — Treatment adherence, survival outcomes and barriers to care of non-Hodgkin lymphoma in Northwest Ethiopia: a mixed-methods study
- Rituximab-containing regimens were administered to 35.3% of patients. — Treatment adherence, survival outcomes and barriers to care of non-Hodgkin lymphoma in Northwest Ethiopia: a mixed-methods study
- Some patients did not receive rituximab because of cost and limited drug availability. — Treatment adherence, survival outcomes and barriers to care of non-Hodgkin lymphoma in Northwest Ethiopia: a mixed-methods study
- Survival did not differ significantly by rituximab receipt, although the p value approached significance. — Treatment adherence, survival outcomes and barriers to care of non-Hodgkin lymphoma in Northwest Ethiopia: a mixed-methods study
- Rituximab exposure was associated with higher treatment abandonment. — Treatment adherence, survival outcomes and barriers to care of non-Hodgkin lymphoma in Northwest Ethiopia: a mixed-methods study